160 Health International Limited
健康160国际有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2656)

POSITIVE PROFIT ALERT

This announcement is made by 160 Health International Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the "**Reporting Period**") and the information currently available to the Company, the Group expects to record a net profit for the Reporting Period ranging from approximately RMB1.0 million to RMB3.0 million, as compared to a loss for the period of RMB19.6 million for the six months ended June 30, 2025 (the "**Corresponding Period Last Year**").

The Group's operating performance during the Reporting Period improved significantly compared to the Corresponding Period Last Year and achieved a turnaround, primarily due to the Group's continued optimization of the business structure during the Reporting Period. During the Reporting Period, the number of hospitals operating in collaboration with the Group's "160AI Hospital" achieved rapid growth, driving a steady increase in the number of paying collaborating medical and healthcare institutions, which promoted the overall growth of revenue from the high-margin business segment of digital healthcare and wellness solutions. Benefiting from this, the Group's gross profit during the Reporting Period increased year-on-year by approximately RMB20.0 million to RMB24.0 million, representing a year-on-year increase of approximately 31.2% to 37.5% compared to the Corresponding Period Last Year.

The information contained in this announcement is only based on the preliminary assessment of the Group's unaudited consolidated management accounts for the Reporting Period and other information currently available to the Company. Such information has not been audited or reviewed by the independent auditor of the Company, nor has it been reviewed by the audit committee of the Company. Such financial information is subject to finalization and necessary adjustments, and the actual interim results of the Group for the six months ended June 30, 2026 may differ from the information contained in this announcement. Further details of the Group's financial results and performance will be disclosed in the Company's interim results announcement for the six months ended June 30, 2026, which is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
160 Health International Limited
Mr. LUO Ningzheng
Chairman of the Board, Executive Director
and Chief Executive Officer

Hong Kong, August 16, 2026

As of the date of this announcement, the Board comprises (i) Mr. LUO Ningzheng, Mr. JI Cuilin, Mr. HUANG Lang and Mr. WANG Lifa as executive Directors; (ii) Mr. LIU Haibin as non-executive Director; and (iii) Mr. WANG Huan, Dr. XU Weiguo and Dr. FAN Ming as independent non-executive Directors.